.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
McKinsey
Fish and Richardson
Accenture
Colorcon
Julphar
Moodys
Baxter
QuintilesIMS

Generated: September 26, 2017

DrugPatentWatch Database Preview

Romark Company Profile

« Back to Dashboard

What is the competitive landscape for ROMARK, and when can generic versions of ROMARK drugs launch?

ROMARK has two approved drugs.

There are three US patents protecting ROMARK drugs.

There are one hundred and twenty-three patent family members on ROMARK drugs in forty-two countries.

Summary for Applicant: Romark

Patents:3
Tradenames:1
Ingredients:1
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Romark
ALINIA
nitazoxanide
TABLET;ORAL021497-001Jul 21, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Romark

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Romark
ALINIA
nitazoxanide
TABLET;ORAL021497-001Jul 21, 2004► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
TABLET;ORAL021497-001Jul 21, 2004► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
TABLET;ORAL021497-001Jul 21, 2004► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002► Subscribe► Subscribe
Romark
ALINIA
nitazoxanide
FOR SUSPENSION;ORAL021498-001Nov 22, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Romark

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,387,598 Composition and galenic formulation suitable for combatting affections of the lower abdomen► Subscribe
6,051,576 Means to achieve sustained release of synergistic drugs by conjugation► Subscribe
5,859,038 Method for treatment of helicobacter pylori infections► Subscribe
5,856,348 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide► Subscribe
5,886,013 Antiviral composition► Subscribe
5,578,621 Benzamide derivatives► Subscribe
6,020,353 2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Romark Drugs

Country Document Number Estimated Expiration
South Africa9803849► Subscribe
African Regional IP Organization (ARIPO)9901675► Subscribe
Australia740022► Subscribe
African Regional IP Organization (ARIPO)645► Subscribe
New Zealand284800► Subscribe
JapanH09509151► Subscribe
Slovakia283947► Subscribe
Cuba23318► Subscribe
European Patent Office0755386► Subscribe
China1158074► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Fuji
Federal Trade Commission
Baxter
Argus Health
Daiichi Sankyo
Boehringer Ingelheim
Moodys
Healthtrust
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot